Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions.

Grundeken MJ, Smits M, Harskamp RE, Damman P, Woudstra P, Hoorweg AJ, Baan J Jr, Arkenbout EK, Piek JJ, Vis MM, Henriques JP, Koch KT, Tijssen JG, de Winter RJ, Wykrzykowska JJ.

Neth Heart J. 2012 Nov;20(11):439-46. doi: 10.1007/s12471-012-0302-x.

2.

First report on long-term clinical results after treatment of coronary bifurcation lesions with the Tryton dedicated bifurcation stent.

Grundeken MJ, Kraak RP, Baan J Jr, Arkenbout EK, Piek JJ, Vis MM, Henriques JP, Koch KT, Tijssen JG, de Winter RJ, Wykrzykowska JJ.

Catheter Cardiovasc Interv. 2014 Nov 1;84(5):759-65.

PMID:
25485348
3.

Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies.

Grundeken MJ, Asgedom S, Damman P, Lesiak M, Norell MS, Garcia E, Bethencourt A, Woudstra P, Koch KT, Vis MM, Henriques JP, Onuma Y, Foley DP, Bartorelli AL, Stella PR, Tijssen JG, de Winter RJ, Wykrzykowska JJ.

EuroIntervention. 2013 Jun 22;9(2):195-203. doi: 10.4244/EIJV9I2A34.

4.

Placement of Tryton Side Branch Stent only; a new treatment strategy for Medina 0,0,1 coronary bifurcation lesions.

Grundeken MJ, Agostoni P, Lesiak M, Koch KT, Voskuil M, de Winter RJ, Wykrzykowska JJ, Stella PR.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E395-402. doi: 10.1002/ccd.24811. Epub 2013 Apr 25.

PMID:
23554121
6.

A prospective multicentre registry, evaluating real-world usage of the Tryton side branch stent: results of the E-Tryton 150/Benelux registry.

Agostoni P, Foley D, Lesiak M, Belkacemi A, Dens J, Kumsars I, Scott B, Oemrawsingh P, Dubois C, Garcia E, Lefèvre T, Stella PR.

EuroIntervention. 2012 Mar;7(11):1293-300. doi: 10.4244/EIJV7I11A204.

7.

Clinical outcome of patients with de novo coronary bifurcation lesions treated with the Tryton Side Branch Stent. The SAFE-TRY prospective multicenter single arm study.

Tarantini G, La Vecchia L, Galli M, Favero L, D'Amico G, Buja P, Russo F, Cabianca E, Napodano M, Musumeci G, Franceschini E, Grassi G, Pavei A, Bonmassari R, Cernetti C, Spedicato L, Caprioglio F, Reimers B, Isabella G.

Int J Cardiol. 2013 Oct 15;168(6):5323-8. doi: 10.1016/j.ijcard.2013.08.008. Epub 2013 Aug 16.

PMID:
24007969
8.

Six-month clinical follow-up of the Tryton side branch stent for the treatment of bifurcation lesions: a two center registry analysis.

Magro M, Wykrzykowska J, Serruys PW, Simsek C, Nauta S, Lesiak M, Stanislawska K, Onuma Y, Regar E, van Domburg RT, Grajek S, Geuns RJ.

Catheter Cardiovasc Interv. 2011 May 1;77(6):798-806. doi: 10.1002/ccd.22767. Epub 2011 Mar 8.

PMID:
20824767
9.

Clinical outcomes after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions treated with a dedicated coronary bifurcation stent.

Grundeken MJ, Lesiak M, Asgedom S, Garcia E, Bethencourt A, Norell MS, Damman P, Woudstra P, Koch KT, Vis MM, Henriques JP, Tijssen JG, Onuma Y, Foley DP, Bartorelli AL, Stella PR, de Winter RJ, Wykrzykowska JJ.

Heart. 2014 Mar;100(6):479-86. doi: 10.1136/heartjnl-2013-304912. Epub 2014 Jan 15.

PMID:
24430096
10.

The Tryton Side Branch Stent™ for the treatment of coronary bifurcation lesions.

Grundeken MJ, Stella PR, Wykrzykowska JJ.

Expert Rev Med Devices. 2013 Nov;10(6):707-16. doi: 10.1586/17434440.2013.848165. Epub 2013 Oct 29. Review.

PMID:
24164662
11.

A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions.

Généreux P, Kumsars I, Lesiak M, Kini A, Fontos G, Slagboom T, Ungi I, Metzger DC, Wykrzykowska JJ, Stella PR, Bartorelli AL, Fearon WF, Lefèvre T, Feldman RL, LaSalle L, Francese DP, Onuma Y, Grundeken MJ, Garcia-Garcia HM, Laak LL, Cutlip DE, Kaplan AV, Serruys PW, Leon MB.

J Am Coll Cardiol. 2015 Feb 17;65(6):533-43. doi: 10.1016/j.jacc.2014.11.031.

12.

Acute procedural and six-month clinical outcome in patients treated with a dedicated bifurcation stent for left main stem disease: the TRYTON LM multicentre registry.

Magro M, Girasis C, Bartorelli AL, Tarantini G, Russo F, Trabattoni D, D'Amico G, Galli M, Gómez Juame A, de Sousa Almeida M, Simsek C, Foley D, Sonck J, Lesiak M, Kayaert P, Serruys PW, van Geuns RJ.

EuroIntervention. 2013 Mar;8(11):1259-69. doi: DOI: 10.4244/EIJV8I11A194.

13.

Double bifurcation lesion treated with double Tryton Sidebranch Stent: first case report.

Unzué L, García E, Almería C.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E477-81. doi: 10.1002/ccd.24858. Epub 2013 Apr 8.

PMID:
23378273
14.

Intermediate term outcomes with bifurcation coronary stenting using the paclitaxel drug-eluting stent: a single centre experience.

Shammas NW, Dippel EJ, Shammas GA, Farland L, Brosius S, Jerin M, Avila A, Gehbauer L, Winter M, Stoakes P, Byrd J, Sharis P, Robken J.

Int J Angiol. 2008 Summer;17(2):88-92.

15.

Serial intravascular ultrasound analysis of complex bifurcation coronary lesions treated with the Tryton Bifurcation Stent in conjunction with an everolimus-eluting stent: IUVANT (Intravascular Ultrasound Evaluation of Tryton Stent) study.

Bartorelli AL, Trabattoni D, Almonacid A, Fabbiocchi F, Montorsi P, Galli S, Grancini L, Ravagnani P, Mintz GS, Kaplan AV, Popma JJ, Maehara A.

Catheter Cardiovasc Interv. 2015 Mar;85(4):544-53. doi: 10.1002/ccd.25629. Epub 2014 Aug 28.

PMID:
25115944
16.

Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.

Gil RJ, Vassilev D, Michalek A, Kern A, Formuszewicz R, Dobrzycki S, Wójcik J, Lesiak M, Kardaszewicz P, Lekston A.

EuroIntervention. 2012 Jul 20;8(3):316-24. doi: 10.4244/EIJV8I3A50.

17.

5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.

JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.

18.

Twelve-month outcomes after coronary stenting with the Genous™ bio-engineered R Stent™ in diabetic patients from the e-HEALING registry.

Damman P, Klomp M, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wójcik J, Sim KH, Tijssen JG, DE Winter RJ; e-HEALING Investigators..

J Interv Cardiol. 2011 Aug;24(4):285-94. doi: 10.1111/j.1540-8183.2010.00624.x. Epub 2011 Jan 31.

PMID:
21281358
19.

First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.

Gil RJ, Vassiliev D, Michałek A, Kern A, Formuszewicz R, Dobrzycki S, Lesiak M, Wójcik J, Kardaszewicz P, Lekston A.

Kardiol Pol. 2012;70(1):45-52.

20.

First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.

Gil RJ, Bil J, Vassiliev D, Iñigo Garcia LA.

J Interv Cardiol. 2015 Feb;28(1):51-60. doi: 10.1111/joic.12180.

PMID:
25689548

Supplemental Content

Support Center